Marco Brughera

Biography

the Vice President of Preclinical Development at Nerviano Medical Sciences (NMS), a pharmaceutical oncology-focused integrated discovery and development company.  He also served as the Managing Director at Accelera, an independent contract research organization with the NMS Group.  From 1999 to 2004, Dr. Brughera held several senior level positions in the areas of research and development with Pharmacia and Pfizer. Prior to 1999, he held various positions at Pharmacia & Upjohn and Farmitalia Carlo Erba SpA, an Italian pharmaceutical company. He currently serves on the Board of Solgenix and Lee’s Pharmaceutical and until early 2014 was a member of the Board of Gentium SpA.  Dr. Brughera earned his degree in veterinary medicine from the University of Milan and is a European Registered Toxicologist. ROSTISLAV RAYKOV Mr. Raykov has served as a director of Fennec Pharma and Chief Executive Officer since July 2009 Mr. Raykov is a General Partner at DCML, a private investment partnership.  Prior to DCML, Mr. Raykov was a co-founder and portfolio manager for Alchem Investment Partners, an event driven hedge fund.  Mr. Raykov also worked as a portfolio manager for Purchase Associates, an event driven hedge fund owned by John Levin & Co. He began his career as a financial analyst in the natural resources group at Bear Stearns. Mr. Raykov graduated from University of North Carolina at Chapel Hill, where he earned a Bachelor of Science degree in business administration.      

Research Interest

the Vice President of Preclinical Development at Nerviano Medical Sciences (NMS), a pharmaceutical oncology-focused integrated discovery and development company.  He also served as the Managing Director at Accelera, an independent contract research organization with the NMS Group.  From 1999 to 2004, Dr. Brughera held several senior level positions in the areas of research and development with Pharmacia and Pfizer. Prior to 1999, he held various positions at Pharmacia & Upjohn and Farmitalia Carlo Erba SpA, an Italian pharmaceutical company. He currently serves on the Board of Solgenix and Lee’s Pharmaceutical and until early 2014 was a member of the Board of Gentium SpA.  Dr. Brughera earned his degree in veterinary medicine from the University of Milan and is a European Registered Toxicologist. ROSTISLAV RAYKOV Mr. Raykov has served as a director of Fennec Pharma and Chief Executive Officer since July 2009 Mr. Raykov is a General Partner at DCML, a private investment partnership.  Prior to DCML, Mr. Raykov was a co-founder and portfolio manager for Alchem Investment Partners, an event driven hedge fund.  Mr. Raykov also worked as a portfolio manager for Purchase Associates, an event driven hedge fund owned by John Levin & Co. He began his career as a financial analyst in the natural resources group at Bear Stearns. Mr. Raykov graduated from University of North Carolina at Chapel Hill, where he earned a Bachelor of Science degree in business administration.